
Quarterly report 2025-Q4
added 01-29-2026
Pro-Dex Cash Flow 2011-2026 | PDEX
Annual Cash Flow Pro-Dex
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Operating Cash Flow |
-1.68 M | 6.22 M | 5.46 M | -847 K | -2.08 M | 4.94 M | 3.33 M | 3.1 M | 3.24 M | 466 K | - | -329 K | -1.27 M | 45 K | 2.9 M |
Depreciation & Amortization |
1.24 M | 1.16 M | 857 K | 726 K | 686 K | 573 K | 438 K | 557 K | 555 K | 614 K | 578 K | 527 K | 582 K | 647 K | 697 K |
Accounts Payables |
4.61 M | 4.51 M | 2.26 M | 3.76 M | 2.29 M | 1.96 M | 2 M | 1.08 M | 1.16 M | 841 K | 1.87 M | 744 K | 844 K | 633 K | - |
Accounts Receivables |
16.4 M | 13.9 M | 9.95 M | 15.4 M | 10.9 M | 5.16 M | 4.1 M | 2.96 M | 3.54 M | 1.47 M | 2.33 M | 1.78 M | 1.34 M | 1.58 M | - |
Total Inventories |
22.2 M | 15.3 M | 16.2 M | 12.7 M | 8.44 M | 8.24 M | 6.24 M | 4.39 M | 3.08 M | 3.57 M | 4.31 M | 2.6 M | 3.83 M | 2.79 M | - |
All numbers in USD currency
Quarterly Cash Flow Pro-Dex
| 2025-Q4 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Operating Cash Flow |
- | - | - | - | 1.89 M | - | - | - | 392 K | - | - | - | 2.89 M | 2.5 M | - | - | 2.7 M | 4.22 M | - | - | -888 K | 1.08 M | -888 K | - | 908 K | 2.56 M | 908 K | - | 636 K | 1.51 M | 636 K | - | 1.06 M | 1.28 M | 1.04 M | - | 255 K | - | - | - | - | - | - | - | 523 K | 263 K | - | - | -512 K | -646 K | -512 K | - | -172 K | -791 K | -172 K | - | 349 K | -6 K | 349 K |
Depreciation & Amortization |
- | - | 23 K | - | 302 K | - | 23 K | - | 283 K | - | 23 K | - | 193 K | 384 K | - | - | 184 K | 366 K | - | - | 150 K | 320 K | 150 K | - | 138 K | 282 K | 138 K | - | 88 K | 195 K | 88 K | - | 153 K | 310 K | 153 K | - | 139 K | 275 K | 139 K | 166 K | 169 K | 334 K | 169 K | 132 K | 127 K | 259 K | 127 K | - | 132 K | 283 K | 132 K | - | 151 K | 298 K | 151 K | - | 169 K | 339 K | 169 K |
Accounts Payables |
4.11 M | 4.61 M | 5.96 M | 5.69 M | 4.44 M | 4.51 M | 3.44 M | 2.91 M | 2.74 M | 2.26 M | 3.07 M | 3.36 M | 3.55 M | 3.76 M | 3.53 M | 2.32 M | 2.48 M | 2.29 M | 2.29 M | 2.47 M | 1.83 M | 1.96 M | 1.96 M | 1.67 M | 1.38 M | 2 M | 2 M | 970 K | 1.2 M | 1.08 M | 1.08 M | 923 K | 943 K | 1.16 M | 1.16 M | 761 K | 1.18 M | 841 K | 841 K | 1.29 M | 1.21 M | 1.87 M | 1.87 M | 830 K | 617 K | 744 K | 744 K | 626 K | 482 K | 844 K | 844 K | 576 K | 1.11 M | 633 K | 633 K | 1.62 M | 1.16 M | 1.21 M | 1.21 M |
Accounts Receivables |
17.9 M | 16.4 M | 15.9 M | 18.5 M | 13.5 M | 13.9 M | 12.5 M | 13.2 M | 11 M | 9.95 M | 10.6 M | 12.2 M | 11 M | 15.4 M | 8.68 M | 8.85 M | 10.1 M | 10.9 M | 10.9 M | 4.62 M | 6.14 M | 5.16 M | 5.16 M | 2.68 M | 3.16 M | 4.1 M | 4.1 M | 3.81 M | 3.62 M | 2.96 M | 2.96 M | 3.15 M | 2.25 M | 3.54 M | 3.54 M | 1.03 M | 1.54 M | 1.47 M | 1.47 M | 1.83 M | 759 K | 2.33 M | 2.33 M | 1.12 M | 1.09 M | 1.78 M | 1.78 M | 1.58 M | 1.36 M | 1.34 M | 1.34 M | 1.18 M | 1.84 M | 1.58 M | 1.58 M | 2.25 M | 2.33 M | 3.13 M | 3.13 M |
Total Inventories |
21.7 M | 22.2 M | 23.4 M | 19.6 M | 16.6 M | 15.3 M | 14.2 M | 15 M | 16.3 M | 16.2 M | 15.1 M | 15.1 M | 15.7 M | 12.7 M | 11.9 M | 9.28 M | 8.91 M | 8.44 M | 8.44 M | 9.15 M | 8.31 M | 8.24 M | 8.24 M | 7.81 M | 6.84 M | 6.24 M | 6.24 M | 4.54 M | 4.56 M | 4.39 M | 4.39 M | 3.2 M | 3.51 M | 3.08 M | 3.08 M | 3.27 M | 3.37 M | 3.36 M | 3.57 M | 4.48 M | 4.25 M | 4.31 M | 4.31 M | 2.88 M | 2.59 M | 2.6 M | 2.6 M | 3.55 M | 3.97 M | 3.83 M | 3.83 M | 3.52 M | 3.48 M | 2.79 M | 2.79 M | 4.73 M | 4.04 M | 3.7 M | 3.7 M |
All numbers in USD currency
Cash Flow Statement is one of the three key financial reports of the company Pro-Dex, reflecting the actual cash inflows and outflows over a certain period. Unlike the income statement, which shows revenues and expenses on an accrual basis, the cash flow statement focuses on real cash flows — how much cash actually came into the company and how much was spent.
Main Sections of the Cash Flow Statement- Operating Activities
This section reflects cash flows related to the company’s core operations: receipts from sales of goods and services, payments to suppliers, employee salaries, taxes, and other operating expenses. Positive cash flow from operating activities indicates the viability of the business and its ability to generate cash. - Investing Activities
Shows cash movements related to the purchase and sale of long-term assets such as real estate, equipment, and investments in other companies. Negative cash flow here often indicates investments in growth, which can be a positive sign. - Financing Activities
Reflects the inflow and outflow of cash related to raising and repaying capital: issuing shares, loans, dividend payments, and loan repayments. This section shows how the company finances its activities and distributes profits.
The cash flow statement is important for investors because it allows them to assess the company’s real liquidity, showing whether it has enough cash to cover current obligations and investments — this is critical for financial stability. Additionally, it helps analyze the quality of earnings, since profits reported in the income statement can be "paper" profits and may not reflect actual cash inflows; the cash flow statement reveals this difference. The presence of free cash is also crucial for evaluating the company’s ability to finance growth and pay dividends, which is important for investors. Attention should also be paid to prolonged negative cash flows from operating activities, as this may serve as a warning sign of potential problems with the core business.
Cash flow statements of other stocks in the Medical instruments sector
| Issuer | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|
|
AtriCure
ATRC
|
$ 28.66 | 1.52 % | $ 1.37 B | ||
|
Atrion Corporation
ATRI
|
- | - | $ 810 M | ||
|
Alcon
ALC
|
$ 79.74 | 2.22 % | $ 40.4 B | ||
|
Ekso Bionics Holdings
EKSO
|
$ 9.63 | 6.76 % | $ 23.4 M | ||
|
The Cooper Companies
COO
|
$ 71.7 | 0.69 % | $ 14.3 B | ||
|
Haemonetics Corporation
HAE
|
$ 59.27 | 3.4 % | $ 2.98 B | ||
|
Harvard Bioscience
HBIO
|
$ 4.66 | 8.0 % | $ 207 M | ||
|
iRhythm Technologies
IRTC
|
$ 120.45 | 4.52 % | $ 3.85 B | ||
|
electroCore
ECOR
|
$ 6.29 | 3.37 % | $ 53.4 K | ||
|
Repro Med Systems
KRMD
|
$ 4.34 | 3.09 % | $ 200 M | ||
|
Isoray
ISR
|
- | 0.03 % | $ 108 M | ||
|
Glaukos Corporation
GKOS
|
$ 119.49 | 2.65 % | $ 5.79 B | ||
|
Masimo Corporation
MASI
|
$ 178.47 | 0.08 % | $ 9.51 B | ||
|
Microbot Medical
MBOT
|
$ 2.35 | -9.27 % | $ 108 M | ||
|
ICU Medical
ICUI
|
$ 129.32 | 2.9 % | $ 3.19 B | ||
|
Milestone Scientific
MLSS
|
$ 0.29 | 3.8 % | $ 23.8 M | ||
|
InfuSystem Holdings
INFU
|
$ 9.73 | 3.73 % | $ 201 M | ||
|
Merit Medical Systems
MMSI
|
$ 70.57 | 3.38 % | $ 4.17 B | ||
|
Envista Holdings Corporation
NVST
|
$ 26.91 | 1.97 % | $ 4.52 B | ||
|
Intuitive Surgical
ISRG
|
$ 458.96 | 1.85 % | $ 164 B | ||
|
Predictive Oncology
POAI
|
- | - | $ 31.1 M | ||
|
LeMaitre Vascular
LMAT
|
$ 115.17 | 0.48 % | $ 2.61 B | ||
|
BioLife Solutions
BLFS
|
$ 20.11 | 1.87 % | $ 926 M | ||
|
Retractable Technologies
RVP
|
$ 0.7 | 4.31 % | $ 21 M | ||
|
Baxter International
BAX
|
$ 17.63 | 2.8 % | $ 9.04 B | ||
|
ResMed
RMD
|
$ 230.26 | 0.61 % | $ 33.6 B | ||
|
STERIS plc
STE
|
$ 224.85 | 1.03 % | $ 22.2 B | ||
|
Pulse Biosciences
PLSE
|
$ 18.92 | 1.34 % | $ 1.28 B | ||
|
Teleflex Incorporated
TFX
|
$ 123.18 | 4.05 % | $ 5.5 B | ||
|
Stereotaxis
STXS
|
$ 1.92 | 2.67 % | $ 175 M | ||
|
STAAR Surgical Company
STAA
|
$ 26.84 | 1.51 % | $ 1.33 B | ||
|
NeuroMetrix
NURO
|
- | 5.05 % | $ 9.02 M | ||
|
Utah Medical Products
UTMD
|
$ 67.15 | 1.9 % | $ 218 M | ||
|
DENTSPLY SIRONA
XRAY
|
$ 12.02 | 2.65 % | $ 2.4 B | ||
|
West Pharmaceutical Services
WST
|
$ 259.96 | 1.33 % | $ 18.8 B | ||
|
AngioDynamics
ANGO
|
$ 10.24 | 4.49 % | $ 418 M | ||
|
Becton, Dickinson and Company
BDX
|
$ 155.43 | 0.78 % | $ 44.7 B | ||
|
Nephros
NEPH
|
$ 2.91 | -1.69 % | $ 30.2 M | ||
|
OraSure Technologies
OSUR
|
$ 3.08 | 4.05 % | $ 226 M | ||
|
Repligen Corporation
RGEN
|
$ 122.59 | 2.07 % | $ 6.83 M |